Skip to main content

Advertisement

Table 2 Laboratory findings in postmenopausal women with rheumatoid arthritis who were given hormone replacement therapy and the control group

From: Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1

  HRT Controls
Laboratory test Baseline 12 months 24 months Baseline 12 months 24 months
Serum TNF-α (pg/ml) 4.1 ± 0.4 (32) 3.8 ± 0.4 (30) 3.6 ± 0.4 (32) 4.4 ± 0.5 (44) 4.1 ± 0.3 (43) 4.2 ± 0.4 (44)
Serum IL-1Ra (pg/ml) 501 ± 49 (35) 678 ± 82 (32)†† 558 ± 85 (35) 494 ± 77 (45) 596 ± 104 (45) 606 ± 128 (45)
Serum IL-6 (pg/ml) 25.7 ± 6.3 (35) 25.1 ± 8.3 (32) 23.1 ± 5.2 (35) 23.2 ± 4.3 (45) 27.1 ± 4.5 (45) 25.6 ± 5.4 (45)
Serum sIL-6R (pg/ml) 851 ± 46 (34) 801 ± 41 (31) 790 ± 36 (34)†,‡ 771 ± 31 (45) 794 ± 35 (45) 804 ± 34 (45)
Serum OPG (pg/ml) 104 ± 19 (30) 133 ± 29 (28) 112 ± 19 (30) 114 ± 14 (43) 109 ± 13 (43) 120 ± 13 (43)
Serum IGF-1 (ng/ml) 80.3 ± 4.9 (29) 81.0 ± 4.0 (24) 92.6 ± 4.6 (29) 78.6 ± 5.3 (40) 78.3 ± 5.0 (40) 77.7 ± 3.9 (40)
ESR (mm) 32.5 ± 3.2 (35) 29.0 ± 3.2 (35) 24.3 ± 2.2 (35)††,‡ 27.3 ± 2.3 (43) 26.6 ± 2.9 (41) 26.7 ± 2.7 (43)
Serum estradiol (pmol/l) 44.4 ± 8.6 (27) 176.7± 31.4 (22)†††,‡‡‡ 160.9 ± 18.7 (27)†††,‡‡‡ 38.0 ± 4.4 (36) 39,0 ± 5,9 (36) 38,9 ± 6,6 (36)
  1. Results for patients with both baseline and 24-month data available with corresponding 12-month data are shown. Values are means ± standard error of the mean. Numbers of patients for whom data were available are shown in parentheses. For comparison with baseline, P ≤ 0.05, ††P < 0.01, †††P < 0.001. For comparison with controls from baseline, P ≤ 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001. ESR = erythrocyte sedimentation rate; IGF-1 = insulin-like growth factor 1; IL-1Ra = IL-1-receptor antagonist; OPG = osteoprotegerin; sIL-6R = soluble IL-6 receptor; TNF-α = tumor necrosis factor α.